Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KINAXO Expands Technology Platform and Secures Additional Venture Capital

Published: Tuesday, May 08, 2007
Last Updated: Tuesday, May 08, 2007
Bookmark and Share
KINAXO is expanding its technology platform include mass spectrometry to serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses.

KINAXO Biotechnologies GmbH is expanding its technology platform to include mass spectrometry. This will allow KINAXO to better serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses.

The in-house mass spectrometry facility is supported by scientific advisors Jesper Olsen and Juergen Cox, two experts from the department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry in Martinsried. KINAXO's technical equipment comprises an ultra-sensitive LTQ Orbitrap mass spectrometer from Thermo Fisher Scientific.

New lead investor Mountain Partners AG and co-investor KfW provided venture capital to fund KINAXO's technology expansion. Seeding investor High-Tech Gruenderfonds as well as KINAXO's shareholders Max Planck Society, BioM AG, Axel Ullrich and Hellmut Kirchner also participated in this financing round.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KINAXO Extends Collaboration with Takeda
KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout ® to assist in research of drugs under development at Takeda.
Tuesday, April 05, 2011
Kinaxo Enters in to an Agreement with AstraZeneca
Under the terms of the agreement, Kinaxo will apply its quantitative mass spec technology platform to support one of AstraZeneca’s oncology programs.
Wednesday, January 05, 2011
Kinaxo Extends its Collaboration with Roche
KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche.
Wednesday, January 13, 2010
Scientific News
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Hunting the Missing Link Between Genetics and the Environment
The International Phenome Centre Network (IPCN) works to transform healthcare through phenomics - the dynamic interactions between our genes and our environment.
Cocaine Test Could Lead to Rapid, Low Cost Roadside Testing
Scientists develop urine and oral fluid diagnostic test for cocaine, utilising a compact mass spectrometer.
The Benefits of a Mediterranean-style Diet
A Western-style diet, with more omega-6 fatty acids than the Mediterranean, dysregulates lipid signaling in aged mice and promotes inflammation.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Rapid Identification of Illicit Designer Drugs
New technique can identify commonly used illicit compounds in as little as 15 seconds.
Enhancing On-line Biological Sample Processing
New techniques are required to meet emerging demands on biopharmaceutical analysis.
Early Warning System for Colorectal Cancer
Potential new diagnostic tool identified for the second most common cancer in the world.
Scientists Develop a Novel Method to Benchmark and Improve the Performance of Protein Measurement Techniques
A wide range of laboratories around the world are benefiting from this work, which enables researchers to analyze or compare the results of quantitative proteomics assays in a standardized way.
Amyloid Study Pinpoints Protein Culprits
A five-year trial at a Brisbane Hospital has increased the accuracy of diagnosing patients with amyloidosis, a group of rare and incurable diseases caused by abnormal protein deposits in tissues and organs.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!